{"id":"asparagine","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Gel","category":"form"},{"label":"Liquid","category":"form"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"l-asparagine","offLabel":[],"synonyms":["asparagine","L-asparagine"],"timeline":[],"brandName":"L-Asparagine","ecosystem":[],"mechanism":{"target":"Amino acid transporter","modality":"Small Molecule","explanation":"Think of L-Asparagine like a Lego brick. When your body needs to build new proteins, it uses amino acids like L-Asparagine to create the necessary building blocks. This process is essential for growth, repair, and maintenance of tissues throughout the body.","oneSentence":"L-Asparagine works by providing the body with a building block for protein synthesis.","technicalDetail":"L-Asparagine is a non-essential amino acid that plays a crucial role in protein synthesis, serving as a precursor to aspartate and glutamate, which are involved in various metabolic pathways, including the synthesis of nucleotides, neurotransmitters, and other biomolecules."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4126","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=asparagine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=asparagine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:50:10.474824","biosimilars":[],"competitors":[{"drugName":"glutamine","drugSlug":"glutamine","fdaApproval":"2004-06-10","relationship":"same-target"},{"drugName":"serine","drugSlug":"serine","fdaApproval":"","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"asparagine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glutamine","brandName":"glutamine","genericName":"glutamine","approvalYear":"2004","relationship":"same-target"},{"drugId":"serine","brandName":"serine","genericName":"serine","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":["Acute Myeloid Leukemia","Leukemia Cutis","Myeloid Neoplasm","Myeloid Sarcoma"],"enrollment":1645,"completionDate":"2027-09-30"},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":["Acute Myeloid Leukemia","Down Syndrome","Myelodysplastic Syndrome","Myeloid Leukemia Associated With Down Syndrome","Myeloproliferative Neoplasm"],"enrollment":280,"completionDate":"2026-06-30"},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1895,"completionDate":"2025-03-31"},{"nctId":"NCT05339529","phase":"NA","title":"Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)","status":"RECRUITING","sponsor":"Nanjing Medical University","startDate":"2022-07-01","conditions":["Acute Aortic Syndrome","Aortic Dissection Type a"],"enrollment":330,"completionDate":"2025-12-31"},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":["Acute Lymphoblastic Leukemia","Acute Undifferentiated Leukemia","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":218,"completionDate":"2024-06-30"},{"nctId":"NCT01856920","phase":"PHASE2","title":"QUILT-3.006 for Recurrent Medullary Thyroid Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2013-03-26","conditions":["Medullary Thyroid Cancer (MTC)"],"enrollment":35,"completionDate":"2018-05-08"},{"nctId":"NCT00005585","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":["Leukemia"],"enrollment":838,"completionDate":""},{"nctId":"NCT04749355","phase":"PHASE2","title":"Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS","status":"UNKNOWN","sponsor":"BioSight Ltd.","startDate":"2021-11-14","conditions":["AML, Adult","MDS","Relapse/Recurrence","Refractory Acute Myeloid Leukemia"],"enrollment":40,"completionDate":"2024-03-14"},{"nctId":"NCT05244590","phase":"NA","title":"Primary Care Consultation for Patients With Palliative Care Needs","status":"COMPLETED","sponsor":"University of Coimbra","startDate":"2022-04-27","conditions":["Palliative Care","Primary Health Care"],"enrollment":53,"completionDate":"2023-02-03"},{"nctId":"NCT03665441","phase":"PHASE3","title":"Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2018-09-15","conditions":["Pancreatic Adenocarcinoma"],"enrollment":512,"completionDate":"2022-01-18"},{"nctId":"NCT02219295","phase":"NA","title":"SEGATROM: Sensory and Gastrointestinal Impact of Taste Receptor Variants on Human Metabolism and Nutrition","status":"COMPLETED","sponsor":"German Institute of Human Nutrition","startDate":"2011-12","conditions":["Disorder of Glucose Regulation"],"enrollment":97,"completionDate":"2014-09"},{"nctId":"NCT00720109","phase":"PHASE2,PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":63,"completionDate":"2020-03-31"},{"nctId":"NCT00537030","phase":"NA","title":"Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-02-11","conditions":["Adult Acute Lymphoblastic Leukemia","Childhood Acute Lymphoblastic Leukemia"],"enrollment":59,"completionDate":""},{"nctId":"NCT02538926","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2018-07-01","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent B Lymphoblastic Lymphoma","Recurrent T Lymphoblastic Leukemia/Lymphoma","Refractory B Lymphoblastic Lymphoma","Refractory T Lymphoblastic Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":0,"completionDate":"2021-07-30"},{"nctId":"NCT03643068","phase":"PHASE1","title":"Phase 1A Study of the Safety of KSP/QRH Dimer","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-08-22","conditions":["Healthy Adults"],"enrollment":26,"completionDate":"2018-10-27"},{"nctId":"NCT00819351","phase":"PHASE3","title":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01-01","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":650,"completionDate":"2016-03-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Gel, Liquid","formulations":[{"form":"GEL","route":"TOPICAL","productName":"EXODERMA Brightening Mellow Foam"},{"form":"GEL","route":"TOPICAL","productName":"EXODERMA Brightening Peeling Gel"},{"form":"LIQUID","route":"TOPICAL","productName":"EXODERMA Calming Toner Pad"}]},"crossReferences":{"NUI":"N0000170238","NDDF":"006909","UNII":"5Z33R5TKO7","CHEBI":"CHEBI:22653","RXNORM":"1157","UMLSCUI":"C0003995","ChEMBL_ID":"CHEMBL58832","KEGG_DRUG":"D09738","DRUGBANK_ID":"DB00174","PDB_CHEM_ID":" ASN","PUBCHEM_CID":"6267","SNOMEDCT_US":"87136001","IUPHAR_LIGAND_ID":"4533","MESH_DESCRIPTOR_UI":"D001216"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16464,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"L-Asparagine, also known as asparagine, is a naturally occurring amino acid. It is a small molecule modality that has been studied for its potential therapeutic effects. However, there is limited information available on its commercial status, approved indications, and safety profile. Further research is needed to fully understand its mechanism of action and potential applications. As a result, it is not currently recognized as a commercially available pharmaceutical agent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}